How does chronic sildenafil prevent vascular oxidative stress in insulin-resistant rats?

Journal of Sexual Medicine

Volumn 7, Issue 1 PART 1, 2010, Pages 79-88

  Oudot, Alexandra ^a   Behr Roussel, Delphine ^b   Le Coz, Olivier ^a   Poirier, Sarah ^a   Bernabe, Jacques ^a   Alexandre, Laurent ^a   Giuliano, François ^a  

^a Pelvipharm   (France)

^b RAYMOND POINCARÉ HOSPITAL   (France)

Author keywords

Endothelium; Insulin resistance; Nitric oxide; Oxidative stress; Pde5 inhibitors; Superoxide

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; INSULIN; NITRIC OXIDE; PROTEIN KINASE B; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SILDENAFIL; SUPEROXIDE;

ABDOMINAL AORTA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENDOTHELIUM; FLUORESCENCE; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERTRIGLYCERIDEMIA; IN VITRO STUDY; INSULIN RESISTANCE; MALE; MONITORING; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; RAT; RESPIRATORY CHAIN; THORACIC AORTA; WESTERN BLOTTING;

EID: 74049127873     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2009.01551.x     Document Type: Article

References (31)

1. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome-a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet Med 2006, 23:469-80.
2. Oudot A, Behr-Roussel D, Compagnie S, Caisey S, Le Coz O, Gorny D, Alexandre L, Giuliano F. Endothelial dysfunction in insulin resistant rats is associated with oxidative stress and cox pathway dysregulation. Physiol Res 2009, 58:499-509.
3. Behr-Roussel D, Oudot A, Compagnie S, Gorny D, Le Coz O, Bernabe J, Wayman C, Alexandre L, Giuliano F. Impact of a long-term sildenafil treatment on pressor response in conscious rats with insulin resistance and hypertriglyceridemia. Am J Hypertens 2008, 21:1258-63.
4. Behr-Roussel D, Oudot A, Caisey S, Coz OL, Gorny D, Bernabe J, Wayman C, Alexandre L, Giuliano FA. Daily treatment with sildenafil reverses endothelial dysfunction and oxidative stress in an animal model of insulin resistance. Eur Urol 2008, 53:1272-80.
5. Behr-Roussel D, Gorny D, Mevel K, Caisey S, Bernabe J, Burgess G, Wayman C, Alexandre L, Giuliano F. Chronic sildenafil improves erectile function and endothelium-dependent cavernosal relaxations in rats: Lack of tachyphylaxis. Eur Urol 2005, 47:87-91.
6. Musicki B, Champion HC, Becker RE, Liu T, Kramer MF, Burnett AL. Erection capability is potentiated by long-term sildenafil treatment: Role of blood flow-induced endothelial nitric-oxide synthase phosphorylation. Mol Pharmacol 2005, 68:226-32.
7. Dias-Junior CA, Cau SB, Oliveira AM, Castro MM, Montenegro MF, Gerlach RF, Tanus-Santos JE. Nitrite or sildenafil, but not BAY 41-2272, blunt acute pulmonary embolism-induced increases in circulating matrix metalloproteinase-9 and oxidative stress. Thromb Res 2009, 124:349-55.
8. Lagoda G, Jin L, Lehrfeld TJ, Liu T, Burnett AL. FK506 and sildenafil promote erectile function recovery after cavernous nerve injury through antioxidative mechanisms. J Sex Med 2007, 4:908-16.
9. Koupparis AJ, Jeremy JY, Muzaffar S, Persad R, Shukla N. Sildenafil inhibits the formation of superoxide and the expression of gp47 NAD[P]H oxidase induced by the thromboxane A2 mimetic, U46619, in corpus cavernosal smooth muscle cells. BJU Int 2005, 96:423-7.
10. Griendling KK, Alexander RW. Oxidative stress and cardiovascular disease. Circulation 1997, 96:3264-5.
11. Wolin MS, Ahmad M, Gupte SA. The sources of oxidative stress in the vessel wall. Kidney Int 2005, 67:1659-61.
12. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-54.
13. Shinozaki K, Kashiwagi A, Nishio Y, Okamura T, Yoshida Y, Masada M, Toda N, Kikkawa R. Abnormal biopterin metabolism is a major cause of impaired endothelium-dependent relaxation through nitric oxide/O2-imbalance in insulin-resistant rat aorta. Diabetes 1999, 48:2437-45.
14. Fleming I, Busse R. Molecular mechanisms involved in the regulation of the endothelial nitric oxide synthase. Am J Physiol Regul Integr Comp Physiol 2003, 284:R1-12.
15. Bivalacqua TJ, Sussan TE, Gebska MA, Strong TD, Berkowitz DE, Biswal S, Burnett AL, Champion HC. Sildenafil inhibits superoxide formation and prevents endothelial dysfunction in a mouse model of secondhand smoke induced erectile dysfunction. J Urol 2009, 181:899-906.
16. Miatello R, Vazquez M, Renna N, Cruzado M, Zumino AP, Risler N. Chronic administration of resveratrol prevents biochemical cardiovascular changes in fructose-fed rats. Am J Hypertens 2005, 18:864-70.
17. Nyby MD, Matsumoto K, Yamamoto K, Abedi K, Eslami P, Hernandez G, Smutko V, Berger ME, Tuck ML. Dietary fish oil prevents vascular dysfunction and oxidative stress in hyperinsulinemic rats. Am J Hypertens 2005, 18:213-9.
18. Shinozaki K, Nishio Y, Okamura T, Yoshida Y, Maegawa H, Kojima H, Masada M, Toda N, Kikkawa R, Kashiwagi A. Oral administration of tetrahydrobiopterin prevents endothelial dysfunction and vascular oxidative stress in the aortas of insulin-resistant rats. Circ Res 2000, 87:566-73.
19. Delbosc S, Paizanis E, Magous R, Araiz C, Dimo T, Cristol JP, Cros G, Azay J. Involvement of oxidative stress and NADPH oxidase activation in the development of cardiovascular complications in a model of insulin resistance, the fructose-fed rat. Atherosclerosis 2005, 179:43-9.
20. Ayala JE, Bracy DP, Julien BM, Rottman JN, Fueger PT, Wasserman DH. Chronic treatment with sildenafil improves energy balance and insulin action in high fat-fed conscious mice. Diabetes 2007, 56:1025-33.
21. Zhao CX, Xu X, Cui Y, Wang P, Wei X, Yang S, Edin ML, Zeldin DC, Wang DW. Increased endothelial nitric-oxide synthase expression reduces hypertension and hyperinsulinemia in fructose-treated rats. J Pharmacol Exp Ther 2009, 328:610-20.
22. Rosano GM, Aversa A, Vitale C, Fabbri A, Fini M, Spera G. Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. Eur Urol 2005, 47:214-20.
23. Costa C, Virag R. The endothelial-erectile dysfunction connection: An essential update. J Sex Med 2009, 6:2390-404.
24. Vlachopoulos C, Ioakeimidis N, Rokkas K, Stefanadis C. Cardiovascular effects of phosphodiesterase type 5 inhibitors. J Sex Med 2009, 6:658-74.
25. Brand MD, Affourtit C, Esteves TC, Green K, Lambert AJ, Miwa S, Pakay JL, Parker N. Mitochondrial superoxide: Production, biological effects, and activation of uncoupling proteins. Free Radic Biol Med 2004, 37:755-67.
26. Das A, Xi L, Kukreja RC. Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis. Essential role of nitric oxide signaling. J Biol Chem 2005, 280:12944-55.
27. Bella AJ, Deyoung LX, Al Numi M, Brock GB. Daily administration of phosphodiesterase type 5 inhibitors for urological and nonurological indications. Eur Urol 2007, 52:990-1005.
28. Hatzimouratidis K, Hatzichristou D. Phosphodiesterase type 5 inhibitors: The day after. Eur Urol 2007, 51:75-88.
29. Uckert S, Hedlund P, Andersson KE, Truss MC, Jonas U, Stief CG. Update on phosphodiesterase (PDE) isoenzymes as pharmacologic targets in urology: Present and future. Eur Urol 2006, 50:1194-207.
30. Mostafa T. Oral phosphodiesterase type 5 inhibitors: Nonerectogenic beneficial uses. J Sex Med 2008, 5:2502-18.
31. Shindel AW. 2009 Update on phosphodiesterase type 5 inhibitor therapy part 1: Recent studies on routine dosing for penile rehabilitation, lower urinary tract symptoms, and other indications (CME). J Sex Med 2009, 6:1794-808.